Background: Piperacillin is considered a moderately protein-bound antibiotic (20%-40%), with albumin being an important binding protein.
INTRODUCTION
Most drugs are bound to serum proteins to various degrees. 1 Piperacillin is generally considered a moderately protein-bound antibiotic (20%-40%), with albumin being an important binding protein. 2 The free drug hypothesis states that only the unbound or free drug is pharmacologically active. Only nonionized free drug can cross the capillary membrane and bind with the receptor for pharmacological action. 1 This is essential for anti-infective drugs because the infection site is typically located outside the blood, and a drug must diffuse through capillary membranes to reach its target. If disease-related barriers or efflux mechanisms do not impair drug distribution, plasma concentrations often represent a reasonable surrogate for tissue concentrations due to the establishment of a rapid equilibrium between plasma and tissues. 3 Under certain conditions, protein binding can be altered, and the actual free drug concentration can differ significantly from the value expected from total drug concentrations. These changes in protein binding may be of clinical importance in some patient groups, such as the critically ill, where hypoproteinemia, liver disorders, and uremia are frequently encountered. In these situations, drug toxicity can occur, as well as therapeutic failure and development of resistance. 3 Therefore, variability in protein binding should be considered in critically ill patients.
Routine therapeutic drug monitoring of piperacillin is not yet common practice, but when antibiotic concentrations are measured, typically the total drug concentration is determined. Unbound drug concentrations are not frequently analyzed due to the (pre)analytical challenges, so these are often predicted from the total piperacillin concentration and the average protein binding found in the literature. In studies, different bound fractions are assumed for piperacillin, ranging from 22% 4 to 30%. 5, 6 This prediction has its limitations, and few data are available about possible confounders.
Equilibrium dialysis (ED) and ultrafiltration (UF) are the 2 most widely used in vitro methods for determining the free fraction of drugs, each having advantages and disadvantages. ED is considered as the gold standard but has its limitation: it needs a long time to reach equilibrium. 7 Another possible disadvantage is volume shifts due to the oncotic pressure of plasma proteins. This causes a dilution of the serum or plasma with buffer, which can lead to changes in pH that influences binding characteristics. ED can also be confounded by the Donnan effect. The Donnan effect is caused by charged macromolecules such as proteins that are not able to pass the membrane. To obtain electrical neutrality, small ions will be unequally distributed over the 2 compartments. The effect can be diminished by adding an electrolyte mixture to the buffer compartment to achieve isotonic concentrations. 8, 9 Although nonspecific adsorption of drugs to the dialysis membrane has been described, this can be solved by measuring the concentration in both the buffer and plasma chamber. The alternative method, UF, is fast and easy to perform but has the disadvantage of potential adsorption to the UF filter. In both methods, variables such as pH and temperature may influence protein binding. 10 Unfortunately, in practice, temperatures for preincubation, handling, and centrifugation of the samples are poorly standardized, with 4, 25, and 378C most frequently used, respectively.
The impact of preanalytical variables has not been thoroughly investigated, and there is a need for standardization. The aim of this study was 3-fold. The main goal was to evaluate the impact of the temperature and the procedure used to isolate unbound piperacillin in plasma on the fu of piperacillin; we compared UF at 48C and 378C with the reference method, ED. We made a major adaptation to the reference method: we used 48C instead of 378C. The second goal was to study intrapatient variability and the third to construct a model to predict unbound piperacillin concentrations from total concentrations.
MATERIALS AND METHODS

Samples
Anonymized left-over Li-heparin plasma samples (n = 41) from 30 patients from the intensive care unit (ICU) were used. All patients received continuous infusion of piperacillin. All blood samples were centrifuged (1885g at 208C for 8 minutes) on arrival in the laboratory (within 1 hour after sampling). The plasma was stored at 2808C until analysis. The study was approved by the ethics committee of Ghent University Hospital (registration number 2015/1385). The final prediction model was tested using 13 anonymized left-over plasma samples from 13 other, different patients from the ICU.
ED
ED was performed using the reusable single-sample Fast Micro-Equilibrium Dialyzer (Harvard Apparatus, Holliston, MA). These Teflon devices consist of 2 chambers of equivalent (500 mL) volume, separated by a semipermeable regenerated cellulose membrane, with molecular weight cutoff of 25,000 Da. Five hundred microliters of plasma were pipetted into the donor chamber and 500 mL dialysis buffer in the acceptor chamber. The dialysis buffer was prepared according to Yue et al. 11 The dialyzer was placed on a universal shaker SM 30B (Edmund Bühler, Hechingen, Germany) at 48C 6 0.18C. To mimic the in vivo situation as closely as possible, temperature was maintained at 378C. However, for ED, we used 48C instead of 378C because total piperacillin concentrations were found not to be stable when stored for 12 hours at 378C. Similar results were found in the literature. At 48C, piperacillin is stable for 5 days. 12 According to the manufacturer's instructions, the dialyzer was placed with the donor chamber up and the acceptor chamber down. After 24 hours, the entire content of both chambers was withdrawn. Piperacillin analysis was performed on the initial plasma samples and on the content of both chambers, as described below. The piperacillin fu was calculated as [concentration (acceptor chamber)/concentration (donor chamber)] and the unbound piperacillin concentration as the fu · initial total piperacillin concentration.
Reproducibility was tested using pooled plasma volumes of 500 mL with a total piperacillin concentration of 86.5 mg/L, which were dialyzed against the same volume of buffer in replicate (n = 4). The mean piperacillin concentrations (6SD) were 39.0 mg/L (62.47 mg/L) and 45.0 mg/L (63.13 mg/L) in the buffer and donor compartment, respectively. The resulting unbound piperacillin concentration was 74.96 mg/L, with a coefficient of variation (CV) of 4.1%.
UF
Samples (500 mL per sample) were incubated in a capped Centrifree Centrifugal Filter Device (Millipore, Billerica, MA), with molecular weight cutoff of 30,000 Da at 378C for 30 minutes. The device was spun at 1880g for 30 minutes at 378C or 48C in a preconditioned Heraeus Labofuge 400 R Centrifuge (Thermo Fisher Scientific, Asheville, NC) with a swingout rotor. From each sample, a 100 mL plasma aliquot underwent the same conditions and was afterward used to measure the total piperacillin concentration. The piperacillin concentration in the ultrafiltrate was measured as described below. The piperacillin fu was calculated as ultrafiltrate conc/total piperacillin conc and the unbound piperacillin concentrations as the fu · initial total piperacillin concentration.
Nonspecific adsorption of piperacillin at the Centrifree UF membrane was minimal (,5%), as evaluated by UF of 2 control samples of pooled ultrafiltrate with a piperacillin concentration of 75.2 and 101.2 mg/L.
Reproducibility was determined by performing UF with a spiked piperacillin sample in quintuplicate and by measuring the free concentration in the ultrafiltrate. The experiment was conducted at 48C. The piperacillin concentration in the plasma sample that also underwent the centrifugation process was 110.7 mg/L. The mean piperacillin concentration (6SD) in the ultrafiltrate was 92.9 mg/L (63.42 mg/L) and the CV 3.69%. This variability is a combination of the imprecision of the UF procedure and the analytical method for determining piperacillin.
Analytical Methods
All piperacillin measurements (total and unbound) were performed on a Waters Acquity Ultra performance liquid chromatography system using a BEH C18 column (1.7 mm, 100 · 2.1 mm) applying a binary gradient elution of water and methanol both containing 0.1% formic acid and 2 mmol/ L ammonium acetate on a tandem quadrupole mass spectrometer in the MRM mode (Waters, Milford). Sample clean-up included protein precipitation with acetonitrile containing the deuterated internal standard (IS) and subsequent dilution of the supernatant with water after centrifugation. The analytical measurement range of the assay was 1 mg/L (limit of quantification) to 250 mg/L. The analytical performance of the assay has been described elsewhere. 13 In accordance with European Medicines Agency guidelines, 14 matrix effect was checked using at least 6 lots of blank matrix from different donors. One mL of plasma from each volunteer was centrifuged in an UF column at 1880g at 48C, and the ultrafiltrate was recovered. For every analyte and the IS, the matrix factor (MF) was calculated for every lot of matrix by dividing the peak area in the presence of the matrix (ultrafiltrate spiked with piperacillin after extraction) by the peak area in the absence of the matrix (in water). The ISnormalized MF was calculated by dividing the MF of the analyte by the MF of the IS. Six samples were spiked after extraction up to a final concentration of 4 mg/L (3 times lower limit of quantification) and 6 samples up to a concentration of 190 mg/L (close to upper limit of quantification). The CV of the samples spiked close to the lower limit of quantification was 5.2%, and the CV of the samples close to the upper limit of quantification was 3.4%. Because neither CV exceeded 15%, the matrix effect was negligible.
Routine Biochemistry Analysis
Immunoglobin A and a1-acid glycoprotein (AAG) were determined on a BN II nephelometer (Siemens, Marburg, Germany) according to the manufacturer's instructions. The concentrations of IgA and a1-acid glycoprotein were assayed using 200-mL plasma samples, which were automatically diluted 1:20 with N Diluent. The serum albumin concentration was determined on the Cobas 8000 c502 analyzer (Roche, Mannheim, Germany) using the bromocresol green method. Total protein was assayed using the biuret method on the Cobas 8000 c701 analyzer (Roche).
Statistical Analysis
Descriptive statistics, Wilcoxon test, calculation of Spearman correlation coefficient (r s ), Passing-Bablok regression, and Bland-Altman analysis were performed using MedCalc (version 11.6.1.0; MedCalc, Ostend, Belgium). Regression analysis was performed with SPSS (version 21; IBM, Armonk, NY). A P value of ,0.05 was considered to be statistically significant. Passing-Bablok linear regression analysis showed no proportional or systematic difference between both methods, if the 95% confidence interval of slope and intercept contained the value of 1 and 0, respectively.
RESULTS
Determination of Unbound Fraction and Free Concentrations
Samples were analyzed for total and unbound piperacillin concentrations using 3 different methods. ED and UF at 48C resulted in median fu that were not significantly different: 88% and 81%, respectively (Wilcoxon, P = 0.173). By contrast, UF at 378C resulted in a significantly higher fu (91%; Wilcoxon, P , 0.0001) compared with ED and UF at 48C (Figs. 1, 2) .
The median total piperacillin concentration was 73 mg/ L. Although median unbound piperacillin concentrations obtained through ED at 48C (67 mg/L) and UF at 48C (63 mg/L) did not differ significantly (Wilcoxon, P = 0.173), those obtained through UF at 378C (66 mg/L) were significantly higher (Wilcoxon, P , 0.0001) than at 48C (Fig. 1B) .
A significant correlation between total and unbound piperacillin concentrations was observed, irrespective of whether the unbound concentrations were determined through UF at 378C (r s = 0.981, P , 0.0001) or through UF at 48C (r s = 0.986, P , 0.0001). The comparison of unbound piperacillin concentrations after UF at 48C with those obtained after UF at 378C and ED 48C also yielded a significant linear correlation (r s = 0.984 and 0.987, respectively, P , 0.0001). Moreover, Passing-Bablok linear regression analysis for the comparison of unbound concentrations after UF at 48C with ED at 48C showed no proportional or systematic difference between both methods. The Cusum test for linearity showed no significant deviation from linearity (Cusum, P = 1.00). Bland-Altman analysis of ED and UF at 48C demonstrated a mean relative bias of 2.8%. The distance between the limits of agreement was clinically acceptable (Fig. 3) .
Influence of Proteins and Total Antibiotic Concentration on fu
Our samples had a diverse protein content with respective ranges: total protein: 32-68 g/L; albumin: 17-41 g/L; IgA: 0.23-5.08 g/L; and AAG: 0.89-3.32 g/L. We evaluated whether we could predict unbound piperacillin concentration from the total piperacillin concentration and the different proteins, and whether the measured protein concentrations added value to our regression model. Not all requirements were fulfilled to construct a linear mixed model with all data (as the number of repeats was too low), so we decided to reduce the data set to the 30 independent patient samples. Because samples were collected randomly, the first sample of each patient was selected for the smaller data set. As can be seen in the scatterplot (Fig. 4) , the distribution width of the data increased as the concentration increased, so we performed a weighted least square linear regression analysis.
With regression analysis, different models were tested with the total piperacillin concentration as an independent variable and the unbound concentration as the dependent variable. The protein concentrations were added one by one as extra explanatory variables.
Total piperacillin was the most important determinant of the unbound piperacillin concentration. None of the proteins tested added significantly to the model (P , 0.05) ( Table 1) .
The equation of the final model was: unbound piperacillin (UF, 378C) = 0.097 + 0.898 (total piperacillin).
Testing the Model
Our model (378C) was validated using a set of 13 fresh samples of different patients with total piperacillin concentrations between 5.95 and 196.13 mg/L.
As shown in Figure 5 , agreement between the observed unbound piperacillin concentration and the predicted unbound piperacillin concentration was acceptable, except for one outlier. There is no apparent explanation for this outlier. We did not measure protein concentrations of these samples. The mean bias of 2.8% in predicted concentrations compared with the measured concentrations is good.
Day-by-Day Intrapatient Variability
Intrapatient variability was studied in the patients from whom multiple samples were collected on different days. For example, the free fraction of patient 1 varied between 88% and 97% when being determined with UF at 378C. The square root of the sum of the squared CVs for all patients was 20.9%. The CV of the combination of the UF procedure and the measurement of the antibiotic concentration is 3.7% (Fig. 6 ).
DISCUSSION
In this study, we compared UF at 48C and 378C with ED (considered the gold standard) at 48C for piperacillin. There were no systematic or proportional differences between UF at 48C and ED at 48C. To mimic the in vivo situation as closely as possible, a temperature of 378C is preferred. However, stability of piperacillin is not guaranteed beyond 1 hour at 378C. Owing to the much shorter processing time of UF, this technique has an important advantage over ED.
In our study of the 41 samples of ICU patients, we found a median piperacillin fu of 91% when using UF at 378C. The fu found in this study was higher than the generally assumed fu value of 60%-80%. Numerous studies demonstrated the higher distribution volume and longer half-life of antibiotics in critically ill patients, but the exact reason for the higher fu remains unknown. A possible explanation lies in the studied population. The free fractions in the reference literature are often determined in noncritically ill patients, in contrast to our study. 2, 15 These data are also in accordance with the study of Wong et al. 16 The piperacillin fu was almost always underestimated when using the degree of protein binding given in the literature. Bauer et al 17 studied the pharmacokinetics of piperacillin in 55 critically ill patients treated with continuous renal replacement therapy and reported a fu of 81% (SD 9.7%).
Another explanation could be that the generally assumed fu of 60%-80% was determined at a lower temperature than 378C. In this study, we found that the mean piperacillin fu, determined by UF, is on average 8% higher at 378C than at 48C, and that this difference is statistically significant (P , 0.001). This finding emphasizes the importance of the UF temperature, which therefore should be clearly mentioned in future publications on this topic. Conclusions should be drawn with caution from the previously published literature where the temperature for preincubation and centrifugation is not controlled or not reported.
We found no significant correlation between piperacillin fu and the total protein, albumin, IgA, and AAG concentrations. These data are in accordance with the study of Wong et al. 16 In the latter observational study with 94 critically ill patients, the fu of piperacillin was determined by UF and compared with the calculated values. No correlation could be demonstrated between piperacillin fu and the protein concentrations either. Analogous to Wong's study, the majority of our patients suffered from hypoalbuminemia (albumin concentration ,35 g/L). Our study adds to previously published studies the use of a standardized analysis method.
Our prediction model was established using weighted least square regression because the distribution width of the data increased as the antibiotics concentration increased. Validation of the model was performed with 13 samples, showing an acceptable mean bias of 2.8% in predicted concentrations compared with the measured concentrations. Using this approach, routine monitoring of unbound piperacillin in ICU patients is not recommended.
Our group published a similar paper in 2015 focusing on vancomycin. Our results are similar to those of Stove et al. 18 Modeling showed that total antibiotic concentration as such was the predominant determinant for the unbound concentration, and the studied protein concentrations were of no added value in predicting the unbound concentration. Similar to the study of Stove et al, we found no statistically significant difference in unbound concentrations after ED and UF at the same temperature. The importance of the temperature during UF was further highlighted by the fact that vancomycin fu after UF at 48C was on average 30.6% lower than that after UF at 378C.
Our study focuses on the critically ill patients. This is an advantage because we studied a specific population with distinct characteristics in whom correct antibiotic treatment is critical. The majority of the patients (88%) suffered from hypoalbuminemia. However, this study has some limitations. First, we did not adjust for pH before UF. The pH from blood remains constant between 7.35 and 7.45 by HCO 3 2 as the buffer system. The pH rises ex vivo because of the continuous loss of CO 2 during sample storage and handling. pH plays an important role in protein binding, for example: vancomycin protein binding drops as pH rises, and all vancomycin is free at pH 9. 19 By contrast, during ED experiments, a buffer was used, which was ---------------------------------------------------------------------------------------------- optimized to correct for the altered pH in the serum compartment. Second, as we worked with anonymized samples, we were not able to consider other patient variables such as comedication, renal function, and other patient characteristics.
CONCLUSIONS
No significant impact of the albumin-, IgA-, total protein-, or a1-acid glycoprotein concentration on the fu was found. Based on the prediction model, we can state that in intensive care patients, the fu of piperacillin is 91% (SD 7%). Based on our results, routine monitoring of unbound piperacillin in ICU patients is not recommended.
We found that the piperacillin fu, determined by UF, is on average 8% higher at 378C (91%) than at 48C (83%). This emphasizes the importance of the temperature used during UF, which should therefore be clearly stated in publications that report on the methodology of UF. 
